BACKGROUND Gastroesophageal reflux disease (GERD) and obesity are associated with esophageal AND AIMS: adenocarcinoma (EAC). We hypothesized that the obesity-EAC relation is mediated by factors secreted from adipocytes. Adiponectin is a peptide secreted by adipocytes, and its plasma levels are inversely associated with obesity. We aimed to estimate the effect of circulating adiponectin on the risk of Barrett's esophagus (BE), an accepted precursor of EAC, controlling for GERD symptoms and other potential confounders.
INTRODUCTION
The incidence of esophageal adenocarcinoma (EAC) in the United States is rising faster than that of any other cancer (1). Barrett's esophagus (BE) is associated with most, if not all, EACs (2) (3) (4) . Risk factors for EAC include gastroesophageal reflux disease (GERD) and obesity (2, 3, 5) . Obesity has also been associated with GERD (5) . Therefore, the effect of obesity on EAC has been proposed to be mediated by a mechanical effect promoting GERD, and thereby promoting BE (6, 7) . As obesity is associated with EAC, even after adjusting for GERD (5, 8) , we hypothesized that the effect of obesity on EAC and BE may not be solely due to the promotion of GERD. Prior studies have shown an association between abdominal obesity and BE, but no association, or a weaker association, between total body obesity and BE (9) (10) (11) . Abdominal adipose tissue is biologically active; circulating factors secreted from adipose tissue may mediate part of the effect of obesity on the development of BE, EAC, or both. Candidate circulating factors include interleukin-6, tumor necrosis factor-α, leptin, ghrelin, adiponectin, insulin-like growth factor-1 or its binding proteins, and others (12) (13) (14) (15) (16) (17) . Adiponectin is a peptide secreted primarily from visceral adipocytes, for which serum levels are inversely associated with obesity (18) . Levels are lower in men than in women, controlling for obesity (19) . Adiponectin inhibits inflammation and promotes apoptosis, and deficiency of adiponectin has been associated with a number of epithelial cancers (18) . We chose a priori to evaluate the role of adiponectin because of these features and due to its stable intrasubject levels across time and in relation to meals (20) (21) (22) (23) (24) . We hypothesized that adiponectin deficiency is a risk factor for BE and performed a case-control study to examine the association between circulating levels of adiponectin and BE among patients undergoing elective upper endoscopy.
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METHODS
Subjects
The study was performed at the University of Michigan Medical Center and the Ann Arbor Veterans Affairs Medical Center. Both centers provide a mix of primary, secondary, and tertiary care. Both cases and controls were recruited when they presented with clinical indications for elective upper endoscopy. Cases were patients with BE of at least 1 cm in length (for the most part, these were prevalent cases), confirmed by histological identification of specialized intestinal metaplasia within the tubular esophagus. Controls were patients without BE, who were individually matched to cases on age (15-yr interval) and veteran/civilian status. If subjects carried a diagnosis of BE from a previous endoscopy, but BE was not confirmed by the endoscopy and biopsies at the time of the study (N = 8, all short-segment on prior endoscopy reports), they were not matched and were excluded from the analysis. Patients were excluded from enrollment if they had prevalent cancer, ascites, esophageal varices, coagulopathy, or a history of esophagectomy, were pregnant, were a hospital inpatient, were younger than 18 or greater than 79 yr of age, or if the indication for endoscopy was weight loss of ≥10% or for placement of a feeding tube. The sample size for the analyses presented is 50 matched case-control pairs. The study was approved by the institutional review boards of both centers, and all subjects provided written, informed consent prior to enrollment.
Questionnaire and Anthropometry
Subjects were asked to complete self-administered questionnaires just prior to the endoscopy. A set of questions regarding the presence, duration, quality, frequency of, and medications for GERD symptoms, including heartburn and reflux, was based on variables previously found to be associated with EAC (25) . The questionnaires also queried history of tobacco use. An important potential confounder of adiponectin deficiency would be abdominal obesity, which is associated with both adiponectin deficiency and BE. Weight, height, abdominal circumference, and hip circumference were measured by a trained assistant prior to the endoscopy, while the subject wore only a hospital gown and undergarments.
Blood Samples
Fasting blood samples were drawn prior to the upper endoscopy. Plasma was separated and stored at −80
• C until analyzed in duplicate for adiponectin using a commercially available colorimetric sandwich enzyme-linked immunosorbent assay (B-Bridge, Sunnyvale, CA). We examined the specificity of the relation between BE and adiponectin by examining a similar relation between BE and C-reactive protein (CRP), serum levels of which are also associated with obesity and have been associated with colorectal cancer (26, 27) . CRP was measured quantitatively in the clinical laboratory of the Ann Arbor VA using the highly sensitive near-infrared particle immunoassay methodology.
Endoscopy and Histology
Upper endoscopy was performed by clinical gastroenterologists at both study sites. The trained assistant was present for all endoscopies and directed the endoscopists to abide by standardized guidelines for diagnosing BE, hiatal hernia, and erosive esophagitis. These guidelines, with example photographs, were posted in each endoscopy room at both study sites. Digital photographs were obtained of the gastroesophageal junction and the squamocolumnar junction in each subject. The photographs were subsequently reviewed by the principal investigator (JHR) to confirm the endoscopic appearance of BE. BE was suspected if salmon-colored mucosa resided proximal to the gastric folds within the tubular esophagus. The length of BE was documented, and four-quadrant mucosal biopsies were obtained every 2 cm for histologic confirmation. The presence and size of any hiatal hernia was documented. One subject with Los Angeles Classification C erosive esophagitis underwent repeat endoscopy after a healing course with a proton pump inhibitor, revealing normal squamous lining. No other subjects without evidence of BE on index endoscopy had erosive esophagitis that was more severe than class B. Pathology specimens were prepared according to the routine clinical protocol and interpreted by clinical pathologists at each study site. The presence of specialized intestinal columnar mucosa was required for the diagnosis of BE.
Statistical Analysis
Data were entered into Microsoft Access (Microsoft Corporation, Redmond, WA), and then imported into SAS 9.1 statistical software for analysis (SAS Institute, Cary, NC). Data were assessed for range and logic inconsistencies. Crosstabs for categorical predictors and correlation coefficients for continuous predictors were used to assess associations between pairs of possible BE predictors among controls. Conditional logistic regression analysis was used to estimate the effect (odds ratio [OR] and 95% confidence interval [CI]) of adiponectin and other factors on BE, controlling for the matching variables. Results are presented for several models, involving adjustment for combinations of GERD duration, smoking history, gender, body mass index (BMI), waist circumference, and waist-to-hip ratio (WHR). Because of the small sample size (50 matched pairs) and the strong association between gender (a known risk factor for BE) and veteran/civilian status (a matching variable), we were not able to adjust for gender plus other covariates in the matched analysis. Thus, separate unconditional logistic regression analyses were conducted, adjusting for the matching variable age but not veteran/civilian status. Age was treated as a continuous variable as similar results were found when using age as a set of indicator variables. In addition, unconditional logistic regression was performed in a set restricted to subjects with GERD symptoms at least once per week while not taking proton pump inhibitors or histamine type 2 receptor antagonists.
RESULTS
As expected, cases and controls were similar in the matching variables: the mean age was 60 yr in both groups, and 36% of each group was of veterans. Most subjects were white, 92% in cases and 96% in controls; 80% of cases and 54% of controls were men. Among controls, the most common indications for the endoscopy were GERD refractory to medications (33%), dysphagia (22%), screening for BE (18%), and irondeficiency anemia (10%). Among cases of BE, 84% were undergoing endoscopy for surveillance of known BE (median time since diagnosis was 5 yr, interquartile range 3-8 yr), and the median length of the columnar segment was 3.0 cm (range 1.0-18.0 cm). Four cases of BE were found to have low-grade dysplasia, two were found to have high-grade dysplasia, and two were found to have invasive adenocarcinoma.
Among controls, the mean plasma level of adiponectin was 11.4 µg/mL, ranging from 1.4 to 29.3 µg/mL. Waist circumference was highly correlated with WHR or BMI among controls without BE (Pearson's correlation coefficient [r] = 0.71, P < 0.0001 for waist circumference and WHR; r = 0.80, P < 0.0001 for waist circumference and BMI). However, BMI and WHR were less correlated with each other (r = 0.22, P = 0.12). Adiponectin levels were weakly to moderately correlated with WHR (r = −0.37, P = 0.008), waist circumference (r = −0.40, P = 0.005), BMI (r = −0.19, P = 0.18), and age (r = 0.38, P = 0.007), and nearly uncorrelated with GERD duration (r = −0.01, P = 0.92). Male controls trended toward lower levels of adiponectin than female controls (mean ± standard deviation 10.3 ± 6.6 µg/mL vs 12.6 ± 5.6 µg/mL, P = 0.19). Veteran and civilian controls had similar adiponectin levels (11.2 ± 6.6 µg/mL vs 11.5 ± 6.1 µg/mL, P = 0.89). Among cases of BE, the mean plasma level of adiponectin was 8.4 µg/mL, ranging from 1.6 to 18.6 µg/mL. Adiponectin was weakly correlated with the number of years since the initial diagnosis of BE (r = 0.24, P = 0.14).
Conditional logistic regression analysis showed that longer GERD duration, male gender, BMI, waist circumference, and WHR were all associated with BE ( Table 1 , models B-F). As hypothesized, lower levels of circulating adiponectin were also associated with BE: for each 10-µg/mL decrement in adiponectin, there was an increased odds of BE (OR 4.7, 95% CI 1.4-15.0). Level of CRP was not associated with BE (OR 0.99, 95% CI 0.64-1.50). The estimated effect of adiponectin was not reduced when adjusting for GERD duration, smoking status, and BMI (Table 1 , model J). When adjusting for abdominal obesity, however, the estimated effect of adiponection was reduced; for example, adjusting for WHR plus the other covariates, the OR for adiponectin deficiency was 2.5 (95% CI 0.49-13.00) ( Table 1 , models K and L).
In order to adjust for gender, we broke the matched pairs and used unconditional logistic regression to estimate effects, adjusting for age but not veteran/civilian status. After adjusting for gender, the estimated effect of adiponectin on BE was reduced, but not eliminated, in these analyses (Table 2) . For example, adjusting for age, GERD duration, gender, and Each model only included the covariates for which results are displayed (1-4 covariates in each model); for instance, model L included adiponectin, GERD duration, smoking status, and waist/hip ratio.
* The odds ratio for a continuous predictor is estimated for a specified difference in that exposure (indicated in parentheses after the predictor). OR (95% CI) = odds ratio (95% confidence interval); BMI = body mass index; CRP = C-reactive protein.
WHR, the estimated OR for adiponectin deficiency was 1.8 (95% CI 0.66-4.70). The estimated effect of male gender was reduced after adjusting for adiponectin, and reduced more so after adjusting for WHR. Restricting the analyses to subjects with GERD symptoms at least once per week while off proton pump inhibitors or histamine type 2 receptor antagonists (45 cases of BE and 34 controls) resulted in similar estimates of the adiponectin effect (Table 3 ). For example, adjusting for age, gender, and WHR, the estimated OR for adiponectin deficiency was 1.7 (95% CI 0.60-4.90). Current or past tobacco smoking remained strongly associated with BE in all analyses.
DISCUSSION
In our case-control study of 50 BE cases and matched controls undergoing elective endoscopy for other clinical indications, we found an inverse association between the circulating Each model only included the covariates for which results are displayed (1-4 covariates in each model), plus age as a continuous variable.
level of adiponectin and the presence of BE. The magnitude of this association was not reduced when adjusting for GERD, tobacco use, and BMI; however, adjustment for gender and abdominal obesity did reduce the association. Although these latter adjustments did not eliminate the association between adiponectin and BE, the small sample size resulted in imprecise OR estimates (wide CIs), making chance an alternative explanation for these findings.
Research on the pathogenesis of BE and EAC has largely focused on GERD as an etiologic agent. However, approximately 40% of EAC patients report never having had GERD symptoms (2, 28) . Furthermore, animal models of severe erosive esophagitis are inefficient at producing the complications of BE or EAC, suggesting that other factors may be necessary (29) . Genetic predisposition may be one such factor, but the human species cannot be evolving rapidly enough to account for the increasing incidence of EAC over the last few decades (1). An environmental or behavioral cause is much more likely. We found that among patients referred for endoscopy, most with GERD, those diagnosed with BE are more likely to have smoked than those patients without BE, raising the possibility that smoking is a risk factor for BE. Nonetheless, tobacco use is on the wane in the United States. In contrast, Jeon et al. have shown that the period effect on the gender-and age-specific prevalence of obesity matches the period effect on the gender-and age-specific incidence of EAC over the last decades, suggesting a possible causal link (30) . While obesity may promote GERD by mechanical or physiologic mechanisms, the association of obesity with * The odds ratio for a continuous predictor is estimated for a specified difference in that exposure (indicated in parentheses after the predictor). OR (95% CI) = odds ratio (95% confidence interval); BMI = body mass index; CRP = C-reactive protein.
EAC remains present even when adjusting for GERD symptoms, suggesting a different pathway (5, 8) . In this study of patients referred for endoscopy for clinical indications, we found that deficiency of plasma levels of adiponectin, a peptide secreted primarily from visceral adipocytes, is associated with BE, even after adjusting for duration of GERD symptoms. Male gender is also widely recognized to be a risk factor for both BE and EAC, but to our knowledge, there has yet to be any documented mechanism for these effects (8) . It is possible that the positive association between male gender and BE might be explained, in part, by a low adiponectin level, which is positively associated with both male gender and BE. The magnitude of the estimate of the effect of male gender was reduced after adjusting for either adiponectin or WHR. Adiponectin is the most abundant gene product of adipocytes, and if it is produced by other human tissues at all, it appears to be produced by them at low levels (19, 31) . Adiponectin levels are inversely associated with the presence of colorectal adenomas and with cancers of the colon, stomach, uterus, breast, and prostate (18, 32) . In a prospective cohort study, low adiponectin was found to be associated with the subsequent development of colorectal cancer (33) . Multiple potential signaling pathways for this association have been described (18, (34) (35) (36) . Adiponectin shares homology with tumor necrosis factor-α, acts on distant tissues to promote apoptosis, suppresses proliferation, and suppresses angiogenesis (18, 37, 38) . Therefore, deficiency of adiponectin may be involved in the promotion and progression of carcinogenesis. One potential mechanism of action is adiponectin's suppression of the extracellular signalregulated kinases 1 and 2 (ERK 1/2) (35). Subjects with BE have abnormal activation of ERK 1/2 in squamous epithelium, promoting proliferation and inhibiting apoptosis; it has been proposed that failure to downregulate ERK 1/2 might promote a metaplastic response to reflux (36) . That failure to downregulate ERK 1/2, and the resultant uncontrolled proliferation, might be due to deficiency of adiponectin. In addition, deficiency of adiponectin might promote uncontrolled esophageal inflammation in the setting of GERD. The lack of an association between BE and levels of CRP (a circulating factor whose levels are also associated with obesity) suggests that the association between BE and deficiency of adiponectin is a specific one and may be causal. Studies of the effects of adiponectin in animal models of esophagitis and in cell line cultures are necessary to determine whether adiponectin deficiency has a causative role in the development of BE and EAC.
Our findings may have been influenced by the use of two imperfect (proxy) measures of visceral fat volume, waist circumference and WHR. Adjusting for those two measures may not have completely controlled for abdominal obesity, and adiponectin's attenuation of the estimated effect of waist circumference or WHR for BE could be due to a closer approximation of visceral fat volume by adiponectin levels than by either of those measures. Given the small sample size and the matched design, we may not have completely adjusted for confounders, and this study cannot provide a precise estimate of the hypothesized adiponectin effect on BE. Nonetheless, the fact that low adiponectin remains associated with BE even when adjusting for GERD suggests a mechanism for the association of visceral fat and BE, aside from the one promoting GERD. Adipocytes secrete many factors into the circulation, many of which have effects on inflammation and some of which might also influence metaplasia or progression of neoplasia. Adiponectin is unlikely to be the only such factor to be associated with BE. Levels of adiponectin are likely to be closely associated with levels of these other unmeasured secreted factors. Our results suggest that the effect of adiponectin may have been confounded by covariates such as obesity and male gender, and we cannot rule out that the adjusted association was a chance finding. Thus, our results suggest that adiponectin and/or abdominal obesity affect the risk of BE, but we cannot precisely separate their effects in this study due to the small sample size. Another limitation is that the control group included patients with multiple indications for endoscopy rather than a specific population at risk for BE, and that might have introduced selection bias in the estimation of effects, but the direction and magnitude of such bias is difficult to predict. However, an analysis restricted to subjects with GERD at least once per week (the group of patients who are recommended to undergo screening for BE) showed similar results. Furthermore, this study cannot determine whether adiponectin deficiency is associated with BE among subjects without GERD. Finally, the study is limited by temporal ambiguity as the measurement of adiponectin did not precede the development of BE.
In summary, we observed that among patients referred for endoscopies, most with GERD, those diagnosed with BE have lower adiponectin levels, on average, than do those without BE. This association may mean that a lower adiponectin level increases the risk of BE, but additional research is needed to make a causal inference. Thus, our findings might partly explain the effects of abdominal obesity and male gender on BE. The relentless obesity epidemic may portend a progressively rising incidence of EAC over the coming decades. Prevention of mortality from EAC will require a fuller understanding of the risk factors and pathogenesis for this cancer type. Identification of relations with additional secreted factors might be exploited to develop panels of biomarkers for the identification of patients at risk for BE and EAC or for the development of novel chemopreventive strategies for EAC. r Adiponectin may suppress tumorgenesis, and its circulating levels are inversely related to the risk of a number of epithelial cancers.
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r Circulating levels of adiponectin are inversely associated with BE among patients referred for endoscopy. r The association between adiponectin level and BE does not appear to be due entirely to confounding by GERD or other measured risk factors for BE.
r Rather than simply a mechanical effect of obesity promoting GERD, the effect of obesity on the risk of BE might be mediated by adiponectin and other circulating factors.
